期刊文献+

拉考沙胺片在中国健康受试者的生物等效性研究

Bioequivalence of lacosamide tablets in Chinese healthy subjects
原文传递
导出
摘要 目的研究拉考沙胺片仿制药与原研药在中国健康受试者中单剂量空腹和餐后条件下给药的生物等效性。方法用单中心、随机、开放、单次给药、两制剂、两周期交叉试验设计,共纳入60例(空腹试验30例,餐后试验30例)成年男性和女性受试者随机交叉给药。分别单次口服受试制剂和参比制剂100 mg,用液相色谱串联质谱法测定血浆中拉考沙胺的浓度。用Phoenix WinNonlin 8.0软件计算主要药代动力学参数。结果空腹组的拉考沙胺片受试制剂和参比制剂主要药代动力学参数:C_(max)分别为(4.69±1.20)和(4.67±1.36)ng·L^(-1),AUC_(0-t)分别为(58.90±8.08)和(58.44±8.48)ng·L^(-1)·h,AUC_(0-∞)分别为(60.61±8.63)和(60.11±9.06)ng·L^(-1)·h,t_(max)分别为0.50(0.16,3.00)和0.33(0.16,3.00)h,t_(1/2)分别为(13.96±1.81)和(13.77±1.79)h。餐后组的拉考沙胺片受试制剂和参比制剂主要药代动力学参数:C_(max)分别为(3.38±0.77)和(3.28±0.63)ng·L^(-1),AUC_(0-t)分别为(57.12±9.70)和(57.21±10.57)ng·L^(-1)·h,AUC_(0-∞)分别为(58.71±10.57)和(58.83±11.51)ng·L^(-1)·h,t_(max)分别为2.50(0.33,6.00)和2.00(0.33,6.01)h,t_(1/2)分别为(13.35±2.06)和(13.31±2.32)h。在空腹及餐后条件下,受试制剂与参比制剂主要药代动力学参数的90%置信区间均在80.00%~125.00%。结论在空腹及餐后条件下,中国健康成年受试者单次口服拉考沙胺片仿制药与原研药具有生物等效性。 Objective To study the bioequivalence of generic drug and original lacosamide tablets in Chinese healthy subjects after single dose under fasting and fed conditions.Methods A single-center,random,open,single-dose,two-preparations,double-period,crossover study was adopted.A total of 60 healthy adult male and female subjects(30 cases of fasting test and 30 cases of fed test)were included in the random crossover administration.Single oral dose 100 mg of test and reference were taken,respectively.Plasma concentration of lacosamide in plasma was determined by liquid chromatography tandem mass spectrometry.The main pharmacokinetic parameters were calculated by Phoenix WinNonlin 8.0 software.Results The main pharmacokinetic parameters of the test and reference preparations of lacosamide tablets in the fasting group were as follows:C_(max) were(4.69±1.20)and(4.67±1.36)ng·mL^(-1);AUC_(0-t) were(58.90±8.08)and(58.44±8.48)ng·L^(-1)·h;AUC_(0-∞)were(60.61±8.63)and(60.11±9.06)ng·L^(-1)·h;tmax were 0.50(0.16,3.00)and 0.33(0.16,3.00)h;t1/2 were(13.96±1.81)and(13.77±1.79)h.The main pharmacokinetic parameters of the test and reference preparations of lacosamide tablets in the fed group were as follows:C_(max) were(3.38±0.77)and(3.28±0.63)ng·L^(-1);AUC_(0-t) were(57.12±9.70)and(57.21±10.57)ng·L^(-1)·h;AUC_(0-∞)were(58.71±10.57)and(58.83±11.51)ng·L^(-1)·h;tmax were 2.50(0.33,6.00)and 2.00(0.33,6.01)h;t1/2 were(13.35±2.06)and(13.31±2.32)h.Under fasting and fed conditions,the 90%confidence intervals of the main pharmacokinetic parameters of the test and reference preparations are both 80.00%-125.00%.Conclusion Under fasting and postprandial conditions,a single oral dose of manyfacturer and original lacosamide tablets in Chinese healthy adult volunteers showed bioequivalence.
作者 单娜 张丽 郭剑 刘峰 余婧 汪莎 惠大永 党艳妮 刘腾恬 龚凤云 王静丽 刘雯 SHAN Na;ZHANG Li;GUO Jian;LIU Feng;YU Jing;WANG Sha;HUI Da-yong;DANG Yan-ni;LIU Teng-tian;GONG Feng-yun;WANG Jing-li;LIU Wen(School of Medicine,Shaanxi Institute of Intrenational Trade&Commerce,Xianyang 712046,Shaanxi Province,China;Shaanxi Buchang Pharmaceutical Co.,Ltd,Xianyang 712000,Shaanxi Province,China;Phase I Clinical Laboratory,Wuhan Infectious Disease Hospital,Wuhan 430040,Hubei Province,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2022年第19期2329-2333,共5页 The Chinese Journal of Clinical Pharmacology
关键词 拉考沙胺 生物等效性 药代动力学 健康受试者 lacosamide bioequivalence pharmacokinetic healthy subject
  • 相关文献

参考文献1

二级参考文献2

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部